The Biostatistics and Data Management (BDM) Core is responsible for all statistical and data management activities for each of the Myeloproliferative Neoplasm Research Consortium (MPN-RC) projects including all clinical trials. Each of the projects presented in this application reflects input from the Director of the BDM Core (Dr. Amylou Dueck, Mayo Clinic) on the design, data management, and biostatistical analysis plan. The BDM Core is constituted to provide state-of-the-art statistical collaboration and data management support to all clinical and translational research projects. The biostatistical and data management components of this Core are integrated at Mayo Clinic under the leadership of Dr. Amylou Dueck, who is also the Director of the Biostatistics Shared Resource of the entire Mayo Clinic Cancer Center which spans across Minnesota, Arizona, and Florida. The Core will provide statistical expertise including experimental design for laboratory studies, statistical modeling, analysis of high- dimensional data, analysis of patient-reported outcomes, design and analyses of correlative studies using biospecimens, and sound clinical trial design, monitoring, and analysis. The Core will also provide state-of-the-art web-based data management through Mayo Clinic's data management infrastructure with all clinical trial, biomarker, and tumor bank data captured in Medidata Rave. This web-based system provides ease of use coupled with an integrated randomization module (Medidata Balance), app-based electronic patient questionnaires (Medidata Patient Cloud), custom reporting, robust data validation routines, and straightforward integration with SAS for seamless overall statistical analysis. Dr. Dueck is an experienced co- investigator on translational and clinical research program grants in hematologic malignancies with extensive collaborations with the MPN-RC investigators. The competencies of the biostatistical and data management components of this Core provide the full spectrum of expertise and operational capacity needed to actively collaborate with the translational and clinical investigators in the formulation of the research protocols, in implementation according to internationally-accepted requirements, and in the statistical analysis of the data from clinical, laboratory, and translational studies. The BDM Core is a critical component of the MPN-RC.

Public Health Relevance

The Biostatistics and Data Management Core will provide the Myeloproliferative Neoplasm Research Consortium (MPN-RC) investigators access to state-of-the-art integrated statistical and data management resources. It provides a mechanism for consistent and compatible data handling and tracking among the projects and ensures the work across the MPN-RC is accomplished in a timely manner and with the utmost statistical rigor. Providing oversight of all MPN-RC related statistical and data management activities through this Core allows for synergies and efficiencies for systemic and programmatic initiatives beyond what can be achieved with individual statistical teams for each project.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
New York
United States
Zip Code
Peeken, Jan C; Jutzi, Jonas S; Wehrle, Julius et al. (2018) Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood 131:2065-2073
Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388
Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787
Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13
Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :
Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587
Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179

Showing the most recent 10 out of 195 publications